AR036891A1 - Rosuvastatina en estados predemenciales - Google Patents

Rosuvastatina en estados predemenciales

Info

Publication number
AR036891A1
AR036891A1 ARP020103895A ARP020103895A AR036891A1 AR 036891 A1 AR036891 A1 AR 036891A1 AR P020103895 A ARP020103895 A AR P020103895A AR P020103895 A ARP020103895 A AR P020103895A AR 036891 A1 AR036891 A1 AR 036891A1
Authority
AR
Argentina
Prior art keywords
rosuvastatina
predemential
states
patient
dementia
Prior art date
Application number
ARP020103895A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR036891A1 publication Critical patent/AR036891A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
ARP020103895A 2001-10-19 2002-10-17 Rosuvastatina en estados predemenciales AR036891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103509A SE0103509D0 (sv) 2001-10-19 2001-10-19 Rosuvastatin in pre demented states

Publications (1)

Publication Number Publication Date
AR036891A1 true AR036891A1 (es) 2004-10-13

Family

ID=20285721

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103895A AR036891A1 (es) 2001-10-19 2002-10-17 Rosuvastatina en estados predemenciales

Country Status (19)

Country Link
US (1) US20060229321A1 (enExample)
EP (1) EP1446123A1 (enExample)
JP (1) JP2005505605A (enExample)
KR (1) KR20040058201A (enExample)
CN (1) CN1604780A (enExample)
AR (1) AR036891A1 (enExample)
BR (1) BR0213434A (enExample)
CA (1) CA2463597A1 (enExample)
CO (1) CO5580773A2 (enExample)
HU (1) HUP0401798A3 (enExample)
IL (1) IL161380A0 (enExample)
IS (1) IS7218A (enExample)
MX (1) MXPA04003631A (enExample)
NO (1) NO20041840L (enExample)
PL (1) PL369573A1 (enExample)
RU (1) RU2004112422A (enExample)
SE (1) SE0103509D0 (enExample)
WO (1) WO2003032995A1 (enExample)
ZA (1) ZA200402844B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1562912A2 (en) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CA2546894C (en) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
CA2573857A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
JP2008526781A (ja) 2005-02-22 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンの製造
KR20070062996A (ko) 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol

Also Published As

Publication number Publication date
HUP0401798A2 (hu) 2005-01-28
EP1446123A1 (en) 2004-08-18
CA2463597A1 (en) 2003-04-24
IS7218A (is) 2004-04-13
HUP0401798A3 (en) 2005-06-28
NO20041840L (no) 2004-05-05
IL161380A0 (en) 2004-09-27
WO2003032995A1 (en) 2003-04-24
US20060229321A1 (en) 2006-10-12
CN1604780A (zh) 2005-04-06
BR0213434A (pt) 2004-11-09
SE0103509D0 (sv) 2001-10-19
JP2005505605A (ja) 2005-02-24
KR20040058201A (ko) 2004-07-03
MXPA04003631A (es) 2004-07-30
RU2004112422A (ru) 2005-04-10
CO5580773A2 (es) 2005-11-30
PL369573A1 (en) 2005-05-02
WO2003032995A8 (en) 2004-06-03
ZA200402844B (en) 2005-01-24

Similar Documents

Publication Publication Date Title
ES2545205T3 (es) Combinación de azelastina y ciclesonida
AR013488A1 (es) COMPOSICIoN GERMICIDA ACUOSA PARA EL TRATAMIENTO O PREVENCIoN DE ENFERMEDADES INFECCIOSAS DE LAS PEZUNAS DE ANIMALES, Y USO DE DICHA COMPOSICIoN
BR0113200A (pt) Combinação terapêutica
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
FI20012017L (fi) Menetelmä ja laite magneettistimulaation annoslaskentaa varten
AR015487A1 (es) Uso de un compuesto de colesterol hidroxilado como agente reductor para preparar una composicion farmaceutica de utilidad en un metodo para inhibirla oxidacion de las lipoproteinas en un mamifero.
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
FI971412A7 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
HRP20040758B1 (hr) Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
PT840601E (pt) Thip para o tratamento de desordens do sono
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
DE50301661D1 (de) Darreichungsform von Ibuprofen-Natrium
NO20015122L (no) Behandling av fibrose ved anvendelse av en antagonist for integrin <alfa>-4-subenheten
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
AR036891A1 (es) Rosuvastatina en estados predemenciales
DOP2001000268A (es) Derivados puente de piperazina
BR0015404A (pt) Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso
BR9809376A (pt) Pregnan-3-ol-20-onas
CR7819A (es) Unidad para dosificacion diaria de melatonina
ATE288254T1 (de) Methode zur behandlung von schlaganfall
ATE361753T1 (de) Die verwendung einer spezifischen dosis von fondaparinux natrium zur behandlung des akuten koronaren syndroms
BR9913242A (pt) Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono

Legal Events

Date Code Title Description
FA Abandonment or withdrawal